Study Evaluating Sirolimus (Rapamune™) in Solid Organ Transplant Recipients
An Open-label Extension Study of the Safety of Long-term Administration of Sirolimus (Rapamune™) in Solid Organ Transplant Recipients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2B7
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1M9
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 2Y9
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2C4
-
Toronto, Ontario, Canada, M5B 1W8
-
-
Quebec
-
Montreal, Quebec, Canada, H2L 2W5
-
-
-
-
California
-
Los Angeles, California, United States, 90057
-
Los Angeles, California, United States, 90095-1752
-
San Diego, California, United States, 92123
-
Stanford, California, United States, 94304
-
-
Florida
-
Tampa, Florida, United States, 33606
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
-
Augusta, Georgia, United States, 30912
-
-
Illinois
-
Chicago, Illinois, United States, 60637
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202-5250
-
-
New York
-
New York, New York, United States, 10029
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28232
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19141
-
Pittsburgh, Pennsylvania, United States, 15213
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425-0777
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Completion of sirolimus/blinded therapy in solid organ clinical trials (with or without CsA) with satisfactory compliance and an adequate safety profile.
- Women of childbearing potential who have a negative pregnancy test before enrollment into this study and who agree to practice either a hormonal or barrier method of birth control throughout the treatment period and for 3 months following discontinuation of sirolimus may be enrolled into the study.
- Signed and dated informed consent
Exclusion Criteria:
- Unstable disease states, which in the opinion of the investigator would present a risk to the patient.
- Known hypersensitivity to macrolide antibiotics
Study Plan
How is the study designed?
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 0468E1-306
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.